Leo-pharma A/s

Union Therapeutics A/s

Leo Laboratories Limited

Bjarne Nørremark

Daniel Rodriguez Greve

Mark Andrews

Kristoffer Månsson

Jef Fensholdt

Xifu Liang

Gunnar Grue-Sørensen

Thomas Högberg

Mogens Larsen

Carsten Ryttersgaard

Andreas Ritzen

Sophie Elisabeth Havez

Lars Kristian Albert Blæhr

Anne Eeg Knapp

Jacob Thorhauge

The present invention relates to novel substituted azetidine dihydrothienopyridines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I)

Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors

The present invention relates to novel substituted azetidine dihydrothienopyridines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I) 

The present invention relates to a compound according to formula (I) wherein X represents NH or O; n is an integer selected from 1-3; Y represents a bond, &#x2014;C(O)O&#x2014;*, &#x2014;C(O)OR&#x2014;* or &#x2014;C(O)NHR&#x2014;*; W is selected from the group consisting of phenyl, pyridyl, (C-C)cycloalkyl and 4-6 membered heterocycloalkyl; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors

The invention relates to novel cyclic hydrocarbon compounds and derivatives thereof, processes for the preparation thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

Cyclic hydrocarbon compounds for the treatment of diseases

The present invention relates to a compound according to formula (I) wherein Rrepresents optionally substituted heteroaryl, and pharmaceutically acceptable salts, hydrates, solvates or pharmaceutically acceptable and physiologically cleavable esters thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. diseases associated with hyperplasia, neoplasia or dysplasia, with said compounds, to methods of treatment of cosmetic indications with said compounds, and to the use of said compounds in the manufacture of medicaments. 

3-O-heteroaryl-ingenol

The invention relates to novel calcium-sensing receptor (CaSR) modulating trifluoromethylphenylene cyclopentylene compounds represented in formula (I) and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments. 

Calcium sensing receptor modulating compounds and pharmaceutical use thereof

Calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I (wherein X is CH or N) and pharmaceutical compositions thereof are useful for treating diseases. 

The invention relates to compounds of general formula I wherein D, E, F, G, W, Y, R, A, R, X, B, Rare as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use&#x2014;alone or in combination with one or more other pharmaceutically active compounds&#x2014;in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer.

Growing community of inventors

Stenløse, Denmark

Bjarne Nørremark